Incyte Corp. Hits New 1-Year High at $67.50 (INCY)
Incyte Corp. (NASDAQ:INCY) shares hit a new 52-week high during mid-day trading on Tuesday , American Banking and Market News reports. The stock traded as high as $67.50 and last traded at $66.67, with a volume of 1,152,669 shares. The stock had previously closed at $66.13.
A number of analysts have recently weighed in on INCY shares. Analysts at Nomura raised their price target on shares of Incyte Corp. to $83.00 in a research note on Tuesday, January 21st. Separately, analysts at Canaccord Genuity raised their price target on shares of Incyte Corp. from $65.00 to $79.00 in a research note on Thursday, January 16th. They now have a “buy” rating on the stock. Finally, analysts at Brean Capital raised their price target on shares of Incyte Corp. from $52.00 to $66.00 in a research note on Tuesday, January 14th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $57.20.
The stock has a 50-day moving average of $59.15 and a 200-day moving average of $42.98. The company’s market cap is $10.634 billion.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.